These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 30866732)

  • 1. Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer.
    Kudryavtseva AV; Lukyanova EN; Kharitonov SL; Nyushko KM; Krasheninnikov AA; Pudova EA; Guvatova ZG; Alekseev BY; Kiseleva MV; Kaprin AD; Dmitriev AA; Snezhkina AV; Krasnov GS
    J Bioinform Comput Biol; 2019 Feb; 17(1):1950003. PubMed ID: 30866732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentially Expressed Genes Associated With Prognosis in Locally Advanced Lymph Node-Negative Prostate Cancer.
    Pudova EA; Lukyanova EN; Nyushko KM; Mikhaylenko DS; Zaretsky AR; Snezhkina AV; Savvateeva MV; Kobelyatskaya AA; Melnikova NV; Volchenko NN; Efremov GD; Klimina KM; Belova AA; Kiseleva MV; Kaprin AD; Alekseev BY; Krasnov GS; Kudryavtseva AV
    Front Genet; 2019; 10():730. PubMed ID: 31447885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
    Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
    BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and validation of hub genes for lymph node metastasis in patients with prostate cancer.
    Xu N; Chen SH; Lin TT; Cai H; Ke ZB; Dong RN; Huang P; Li XD; Chen YH; Zheng QS
    J Cell Mol Med; 2020 Apr; 24(8):4402-4414. PubMed ID: 32130760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression.
    Qian J; Hirasawa K; Bostwick DG; Bergstralh EJ; Slezak JM; Anderl KL; Borell TJ; Lieber MM; Jenkins RB
    Mod Pathol; 2002 Jan; 15(1):35-44. PubMed ID: 11796839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole pelvis radiotherapy for pathological node-positive prostate cancer : Oncological outcome and prognostic factors.
    Poelaert F; Fonteyne V; Ost P; De Troyer B; Decaestecker K; De Meerleer G; De Visschere P; Claeys T; Dhondt B; Lumen N
    Strahlenther Onkol; 2017 Jun; 193(6):444-451. PubMed ID: 28101585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of prognosis biomarkers of prostatic cancer in a cohort of 498 patients from TCGA.
    Chen Z; Hu H
    Curr Probl Cancer; 2019 Dec; 43(6):100503. PubMed ID: 31563279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.
    Kalogirou C; Spahn M; Krebs M; Joniau S; Lerut E; Burger M; Scholz CJ; Kneitz S; Riedmiller H; Kneitz B
    Int J Mol Sci; 2013 Oct; 14(11):21414-34. PubMed ID: 24173237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
    Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of prostate carcinoma death in patients with lymph node metastasis.
    Cheng L; Zincke H; Blute ML; Bergstralh EJ; Scherer B; Bostwick DG
    Cancer; 2001 Jan; 91(1):66-73. PubMed ID: 11148561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of radical prostatectomy and lymph node dissection in lymph node-positive prostate cancer: a systematic review of the literature.
    Gakis G; Boorjian SA; Briganti A; Joniau S; Karazanashvili G; Karnes RJ; Mattei A; Shariat SF; Stenzl A; Wirth M; Stief CG
    Eur Urol; 2014 Aug; 66(2):191-9. PubMed ID: 23735200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.
    Varinot J; Furudoï A; Drouin S; Phe V; Penna RR; Roupret M; Bitker MO; Cussenot O; Compérat E
    Virchows Arch; 2016 May; 468(5):619-22. PubMed ID: 26931741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence.
    Spahn M; Kneitz S; Scholz CJ; Stenger N; Rüdiger T; Ströbel P; Riedmiller H; Kneitz B
    Int J Cancer; 2010 Jul; 127(2):394-403. PubMed ID: 19585579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Landscape of chromosome number changes in prostate cancer progression.
    Braun M; Stomper J; Kirsten R; Adler D; Vogel W; Böhm D; Wernert N; Kristiansen G; Perner S
    World J Urol; 2013 Dec; 31(6):1489-95. PubMed ID: 23512229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
    Sanguedolce F; Cormio A; Brunelli M; D'Amuri A; Carrieri G; Bufo P; Cormio L
    Clin Genitourin Cancer; 2016 Apr; 14(2):117-21. PubMed ID: 26774207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear C-MYC expression level is associated with disease progression and potentially predictive of two year overall survival in prostate cancer.
    Zeng W; Sun H; Meng F; Liu Z; Xiong J; Zhou S; Li F; Hu J; Hu Z; Liu Z
    Int J Clin Exp Pathol; 2015; 8(2):1878-88. PubMed ID: 25973080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.